Long-term tDCS Tinnitus Treatment

The Transcranial Direct Current Stimulation Treatment of Tinnitus and Its Psychiatric Comorbidities

The study was designed to evaluate a therapeutic effect of tDCS in the treatment of tinnitus and its comorbidities (anxiety, depresion) and to evaluate the associated quality of life.

In the randomized, double-blinded, sham-controlled trial, 39 participants (active n=19, sham n=20) underwent bilateral dorsolateral prefrontal cortex (DLPFC) tDCS (anode over right DLPFC, cathode left DLPFC, current of 1.5 mA, 20 minutes, 6 sessions in 2 weeks). Tinnitus Functional Index (TFI), Iowa Tinnitus Handicap Questionnaire (ITHQ), Beck Anxiety Inventory (BAI), Zung Self-Rating Depression Scale (SDS), and WHO-Quality of Life-BREF were employed in 4 evaluation points, including the follow-ups of 6 weeks and six months.

Study Overview

• Status: Completed
• Conditions: Tinnitus
• Intervention / Treatment: Device: Transcranial Direct Current Stimulation; Device: Sham Transcranial Direct Current Stimulation

Detailed Description

A prospective, randomized, double-blinded, placebo-controlled, two-arm trial was conducted at the Department of Psychiatry, General University Hospital in Prague, Czechia. The research was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of General University Hospital in Prague, Czechia, in 2019 under the reference number 531/19 S-IV.

Participants were recruited through the recruitment campaign of the Department of Psychiatry, which was supported by outpatient services of several neurological, psychiatric, internal, and otorhinolaryngological departments in several university hospitals around Prague. All participants were required to sign written consent with the trial, anonymized data, the European Union General Data Protection Regulation (GDPR), and were fully informed about the trial's goals, risks, and requirements. Participation was not associated with any financial reward.

The participation was offered to persons at least 18 years of age (on the day of signing the consent) with a history of tinnitus lasting at least six months. The investigators excluded persons contraindicated to tDCS - such as those with epilepsy, intracranial masses or metallic objects, pregnancy, and heart conditions. The investigators also excluded persons with a history of alcohol and drug abuse, persons unwilling to sign the informed consent or persons who underwent any other tinnitus therapy in the last six months. The investigators intended to discontinue the treatment in any participant developing any severe adverse effect (significant exacerbation of tinnitus, epileptic seizure, severe headache, or any adverse effect deemed severe enough by the participants) and in participants noncompliant or unwilling to participate further with the trial and its follow-ups. The investigators required the participants not to alter their medication at least six months before the trial if any was used.

• Study Type: Interventional
• Enrollment (Actual): 44
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Czechia
  • Czech Republic
    • Prague, Czech Republic, Czechia, 12000
      • Psychiatric Department, General University Hospital and 1st Faculty of Medicine, Prague

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Nonpulsatile tinnitus for at least 6 months
• 18 and more years of age

Exclusion Criteria:

• Pregnancy
• Unstable cardiovascular condition
• History of seizures
• Intracranial masses
• Intracranial metalic objects
• History of alcohol or drug abuse
• Unwillingness to sign the informed consent
• Inability to pass the follow-up
• Unstable medication for at least 6 months prior to the enrollment
• Other stimulation method for at least 6 months prior to the enrollmment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Active group; The investigators aimed for six sessions of anodal stimulation over the right DLPFC (F4 in 10-20 EEG system) with cathode above the left DLPFC (F3) using HDCstim by Newronika S.r.l., Italy. The therapy was administered over two weeks (Mon, Wed, Fri) to ensure a washout period of 48 to 72 hours between applications. The current of 1.5 mA was delivered via silicone electrodes inserted into saline (0.9%) filled cellulose sponges, both 5x5cm (Current Density of 0.6 A/m2), for 20 minutes with 20 seconds of both ramp-up and ramp-down. An International 10-20 EEG system was used to determine the stimulation location, and dedicated EEG caps were used to ensure consistency between applications.	Device: Transcranial Direct Current Stimulation; Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
PLACEBO_COMPARATOR: Sham group; The sham (placebo) was administered using the same devices with a preprogrammed sham protocol (using HDCprog by Newronika S.r.l., Italy) of 20 minutes to be virtually indistinguishable from the active stimulation.	Device: Sham Transcranial Direct Current Stimulation; The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tinnitus Functional Index (TFI) at T1 (baseline)	A questionaire evaluating 8 subdomains of tinnitus. A total minimal score=0, maximum score=250. Higher score means generally more severe form of tinnitus.	The measurement was established as a baseline prior to the stimulation series. (at T1)
Changes in Tinnitus Functional Index (TFI) at T2	Changes compared to the baseline (T2-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T2 (after the 6th stimulation, 2 weeks since T1)
Changes in Tinnitus Functional Index (TFI) at T3	Changes compared to the baseline (T3-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T3 (6 weeks since T1)
Changes in Tinnitus Functional Index (TFI) at T4	Changes compared to the baseline (T4-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T4 (6 months since T1)
Iowa Tinnitus Handicap Questionnaire version 1 (ITHQ) at T1 (baseline)	A questionnaire evaluating 3 subdomains of tinnitus and its handicap. A total minimal score=0 %, maximum score=100%. Higher score means generally more severe form of tinnitus.	The measurement was established as a baseline prior to the stimulation series. (at T1)
Changes in Iowa Tinnitus Handicap Questionnaire version 1 (ITHQ) at T2	Changes compared to the baseline (T2-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T2 (after the 6th stimulation, 2 weeks since T1)
Changes in Iowa Tinnitus Handicap Questionnaire version 1 (ITHQ) at T3	Changes compared to the baseline (T3-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T3 (6 weeks since T1)
Changes in Iowa Tinnitus Handicap Questionnaire version 1 (ITHQ) at T4	Changes compared to the baseline (T4-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T4 (6 months since T1)
Beck Anxiety Inventory (BAI) at T1 (baseline)	A standardized questionaire to evaluate the symptoms of anxiety. Minimum=0 points, maximum=63 points. A higher score means generally more severe anxiety.	The measurement was established as a baseline prior to the stimulation series. (at T1)
Changes in Beck Anxiety Inventory (BAI) at T2	Changes compared to the baseline (T2-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T2 (after the 6th stimulation, 2 weeks since T1)
Changes in Beck Anxiety Inventory (BAI) at T3	Changes compared to the baseline (T3-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T3 (6 weeks since T1)
Changes in Beck Anxiety Inventory (BAI) at T4	Changes compared to the baseline (T4-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T4 (6 months since T1)
Zung Self-Rating Depression Scale (SDS) at T1 (baseline)	A standardized questionaire focusing on symptoms of depression. The scale calculates SDS index from the raw data - minimal SDS index=25 points; maximal SDS index=100 points. Higher SDS index means generally more severe depression.	The measurement was established as a baseline prior to the stimulation series. (at T1)
Changes in Zung Self-Rating Depression Scale (SDS) at T2	Changes compared to the baseline (T2-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T2 (after the 6th stimulation, 2 weeks since T1)
Changes in Zung Self-Rating Depression Scale (SDS) at T3	Changes compared to the baseline (T3-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T3 (6 weeks since T1)
Changes in Zung Self-Rating Depression Scale (SDS) at T4	Changes compared to the baseline (T4-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T4 (6 months since T1)
The World Health Organization Quality Of Life (WHOQOL)-BREF at T1 (baseline)	An abbreviated version of WHO questionaire evaluating 4 domains of quality of life during the therapy. The outcomes are calculatefd are on a scale ranging between 0-100%. Higher scores mean generally higher perceived quality of life.	The measurement was established as a baseline prior to the stimulation series. (at T1)
Changes in The World Health Organization Quality Of Life (WHOQOL)-BREF at 2	Changes compared to the baseline (T2-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T2 (after the 6th stimulation, 2 weeks since T1)
Changes in The World Health Organization Quality Of Life (WHOQOL)-BREF at 3	Changes compared to the baseline (T3-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T3 (6 weeks since T1)
Changes in The World Health Organization Quality Of Life (WHOQOL)-BREF at 4	Changes compared to the baseline (T4-T1) were calculated and further statistically compared between the groups. A negative difference to the baseline means an improvement.	Measured at T4 (6 months since T1)

Collaborators and Investigators

• Sponsor: Charles University, Czech Republic
• Investigators: Principal Investigator: Tadeas Mares, M.D., Psychiatric Department, General University Hospital and 1st Faculty of Medicine, Prague; Study Director: Martin Anders, M.D., Ph.D., Psychiatric Department, General University Hospital and 1st Faculty of Medicine, Prague; Principal Investigator: Jozef Buday, M.D., Ph.D., Psychiatric Department, General University Hospital and 1st Faculty of Medicine, Prague

Publications and helpful links

General Publications

• Mares T, Albrecht J, Buday J, Podgorna G, Le TH, Magyarova E, Poshor K, Halik J, Buna J, Capek V, Kostylkova L, Klasova J, Fabian V, Anders M. Long-term effect of transcranial direct current stimulation in the treatment of chronic tinnitus: A randomized, placebo-controlled trial. Front Psychiatry. 2022 Oct 13;13:969800. doi: 10.3389/fpsyt.2022.969800. eCollection 2022.

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 1, 2019
• Primary Completion (ACTUAL): February 28, 2022
• Study Completion (ACTUAL): February 28, 2022

Study Registration Dates

• First Submitted: June 20, 2022
• First Submitted That Met QC Criteria: June 27, 2022
• First Posted (ACTUAL): June 29, 2022

Study Record Updates

• Last Update Posted (ACTUAL): June 29, 2022
• Last Update Submitted That Met QC Criteria: June 27, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Keywords: tDCS; depression; anxiety; tinnitus; neurostimulation
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Otorhinolaryngologic Diseases; Ear Diseases; Sensation Disorders; Hearing Disorders; Tinnitus
• Other Study ID Numbers: 531/19 S-IV

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: IPD can be shared upon request from a verified researcher.
• IPD Sharing Time Frame: Data will be available after the final publication, indefinitely
• IPD Sharing Access Criteria: Upon individual request by a verified researcher.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No